SCHEMBL197795

SCHEMBL197795

Fc1cc2nc(-c3ccc(Cl)cc3)n(C(COc3ccncc3)C3CCCCC3)c2cc1F

nearest known ligand 0.55

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 19/20 0.55
CYP3A4 P08684 6/20 0.55
CYP2C9 P11712 6/20 0.55
CYP2D6 P10635 5/20 0.55
KCNH2 Q12809 5/20 0.55
PDE6D O43924 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL193619 0.92 PDE6D (0.59) NR1H4CYP3A4CYP2C9CYP2D6KCNH2
SCHEMBL198392 0.90 NR1H4 (0.52) NR1H4CYP3A4CYP2C9CYP2D6KCNH2
SCHEMBL197218 0.88 NR1H4 (0.65) NR1H4CYP3A4CYP2C9CYP2D6KCNH2
SCHEMBL197611 0.87 NR1H4 (0.58) NR1H4CYP3A4CYP2C9CYP2D6KCNH2
SCHEMBL197751 0.86 NR1H4 (0.54) NR1H4CYP3A4CYP2C9CYP2D6KCNH2
Bicarbonate SCHEMBL14796784 0.86 NR1H4 (0.56) NR1H4CYP3A4CYP2C9CYP2D6KCNH2
SCHEMBL198734 0.85 NR1H4 (0.55) NR1H4CYP3A4CYP2C9CYP2D6KCNH2
SCHEMBL197767 0.85 NR1H4 (0.58) NR1H4CYP3A4CYP2C9CYP2D6KCNH2
SCHEMBL197314 0.85 NR1H4 (0.55) NR1H4CYP3A4CYP2C9CYP2D6KCNH2
Bicarbonate SCHEMBL14796775 0.85 NR1H4 (0.55) NR1H4CYP3A4CYP2C9CYP2D6KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2321282-B1 NEW BENZIMIDAZOLE DERIVATIVES HOFFMANN LA ROCHE (CH) 2013-03-27 EP claimed
US-8088930-B2 Benzimidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2012-01-03 US claimed
EP-2321282-A1 NEW BENZIMIDAZOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-05-18 EP claimed
WO-2010028981-A1 NEW BENZIMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-03-18 WO claimed
US-20100063101-A1 NEW BENZIMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-03-11 US claimed
EP-2321282-B1 NEW BENZIMIDAZOLE DERIVATIVES HOFFMANN LA ROCHE (CH) 2013-03-27 EP disclosed
US-8088930-B2 Benzimidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2012-01-03 US disclosed
EP-2321282-A1 NEW BENZIMIDAZOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-05-18 EP disclosed
WO-2010028981-A1 NEW BENZIMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-03-18 WO disclosed
US-20100063101-A1 NEW BENZIMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063101-A1 NEW BENZIMIDAZOLE DERIVATIVES CYP3A7, ECI1, CYP2B6 NR1H4 292/4885CYP3A4 4/4885CYP2C9 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.